Sage Journals: Discover world-class research

Open access

Review article

First published 2025

First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma

Silvia Marchesi, Carolina Sciortino, Julian Etessami [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2023

Comparing treatment and outcomes in advanced esophageal,gastroesophageal junction,and gastric adenocarcinomas: a population-based study

Marieke Pape, Pauline A. J. Vissers, Willemieke P. M. Dijksterhuis [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2025

Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

Shixian Liu, Kaixuan Wang, Ruixue Wang [...]

Therapeutic Advances in Gastroenterology

Free access

Research article

First published 2017-4

Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study

Sebastian Ochenduszko, Mirosława Puskulluoglu, Kamil Konopka [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2021

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

Hye Sook Han, Bum Jun Kim, Hee-Jung Jee [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2026

Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis

Jia Wang, Baolong Ding, Zhuying Jing [...]

Therapeutic Advances in Medical Oncology

Retricted access

Review article

First published 2025-12

Zolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal Adenocarcinoma

Gabrielle L. Gorwitz, David L. DeRemer

Annals of Pharmacotherapy

Open access

Research article

First published 2023

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer,gastroesophageal junction cancer,and esophageal adenocarcinoma: a cost-effectiveness analysis

Xueqiong Cao, Mingming Zhang, Na Li [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2021

External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2026

Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2–Positive,HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Review

Matheus Sewastjanow-Silva, Mok Oh, Lawrence Chang [...]

Clinical Medicine Insights: Oncology

Search results